1. |
Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford), 2010, 49(8): 1483-1489.
|
2. |
Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. Clin Exp Rheumatol, 2021, 39(5): 1108-1118.
|
3. |
Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis, 2011, 8(4): 225-231.
|
4. |
王美华, 康区欧, 王志强, 等. 2022版成人特发性肺纤维化和进展性肺纤维化临床实践指南解读. 中国呼吸与危重监护杂志, 2022, 21(6): 381-385.
|
5. |
Sumikawa H, Johkoh T, Ichikado K, et al. Usual interstitial pneumonia and chronic idiopathic interstitial pneumonia: analysis of CT appearance in 92 patients. Radiology, 2006, 241(1): 258-266.
|
6. |
Chen N, Diao CY, Gao J, et al. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Semin Arthritis Rheum, 2022, 55: 152004.
|
7. |
Li LL, Gao S, Fu Q, et al. A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol, 2019, 38(11): 3169-3178.
|
8. |
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med, 2019, 381(18): 1718-1727.
|
9. |
Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med, 2013, 107(8): 1247-1252.
|
10. |
Carnevale A, Silva M, Maietti E, et al. Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests. Clin Rheumatol, 2021, 40(1): 213-219.
|
11. |
Zhang YF, Li HB, Wu NW, et al. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol, 2017, 36(4): 817-823.
|
12. |
Mena-Vázquez N, Godoy-Navarrete FJ, Manrique-Arija S, et al. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol, 2021, 40(1): 133-142.
|
13. |
Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs, 2014, 74(4): 443-450.
|
14. |
Ali AA, Iqbal MP, Hussain MA, et al. Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan. J Pak Med Assoc, 1998, 48(1): 3-6.
|
15. |
Mochizuki T, Ikari K, Yano K, et al. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol, 2019, 29(3): 413-417.
|
16. |
Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford), 2002, 41(3): 262-267.
|
17. |
Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J, 2021, 57(2): 2000337.
|
18. |
Liu L, Fang CX, Sun B, et al. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China. Int J Rheum Dis, 2022, 25(7): 795-802.
|
19. |
Dawson JK, Quah E, Earnshaw B, et al. Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int, 2021, 41(6): 1055-1064.
|